<DOC>
	<DOC>NCT00546494</DOC>
	<brief_summary>This is a study to determine the utility of Effexor® (venlafaxine) in achieving response, including time to response, maintaining remission, and time to remission as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor® (venlafxine) on the various cluster of symptom scales in the 17-item HAM-D.</brief_summary>
	<brief_title>Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA: Patients meeting criteria for a diagnosis of major depression, single or recurrent episode as described by the DSMIV manual (appendix 1). A HAMD 17 total score of at least 16 at baseline (DSMIV manual, appendix 2). Patients above 18 years of age who meet the eligibility requirements. EXCLUSION CRITERIA: Patients taking MAOI's within 2 weeks prior to the survey. Patients known to be suffering from bipolar disorder or schizophrenia. Patients who are treatmentresistant, i.e., in the past 3 years have failed (a) three previous adequate trials of greater than or equal to 2 classes of antidepressant medication, or (b) electroconvulsive therapy. Drug or alcohol dependence or abuse in the past 6 months per DSM IV criteria.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>